Figure 2
From: Galectin-3 is associated with a poor prognosis in primary hepatocellular carcinoma
Decreased galectin-3 and CD34 expression in surgical specimens of primary hepatocellular carcinoma (n?=?165) detected by immunohistochemistry. (A1-4) Immunohistochemical staining for galectin-3 expression in human hepatocellular carcinoma. (A1) Adjacent non-tumorous tissues. (A2) Poorly differentiated hepatocellular carcinoma. (A3) Moderately differentiated hepatocellular carcinoma. (A4) Well-differentiated hepatocellular carcinoma. (A5-6) Immunohistochemical staining for CD34 antigen in human hepatocellular carcinoma. Original magnification for A1–A6, ×200. (B) Based on the results of immunohistochemical staining, the HCC patients (n?=?165) were divided into high galectin-3 expression (n?=?135) and low galectin-3 expression (n?=?30) after resection. Log-rank test revealed that patients in the low-expression group exhibited significantly better survival than those in the high-expression group (P?<?0.01).